No Data
No Data
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study
Acumen Pharmaceuticals (ABOS) said Wednesday that it has dosed the first patient in the phase 2 study of sabirnetug for patients of early Alzheimer's disease. The phase 2 trial is currently enrolling
Acumen Pharmaceuticals Says First Patient Dosed In ALTITUDE-AD, A Phase 2 Clinical Trial Of Sabirnetug In Early Alzheimer's Disease
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzh
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Acumen Pharmaceuticals Announces First Patient Dosed In ALTITUDE-AD Phase 2 Clinical Trial Of Sabirnetug (ACU193) In Early Alzheimer's Disease
Express News | Acumen Pharmaceuticals Inc: Expects to Initiate a Phase 1 Bioavailability Study to Support a Subcutaneous Dosing Option of Sabirnetug in Mid-2024
Express News | Acumen Pharmaceuticals Announces First Patient Dosed in Altitude-Ad, a Phase 2 Clinical Trial of Sabirnetug (Acu193) in Early Alzheimer’s Disease